Literature DB >> 11595289

DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques.

S Cherpelis1, X Jin, A Gettie, D D Ho, S W Barnett, I Shrivastava, L Stamatatos.   

Abstract

Rhesus macaques immunized with the HIV-1 SF162DeltaV2 gp140 envelope using the DNA-prime plus protein-boost vaccination methodology, developed HIV envelope-specific T-cell lymphoproliferative responses and potent neutralizing antibodies. To evaluate the protective potential of these antibodies during acute infection, the animals were depleted of their CD8+ T lymphocytes using specific monoclonal antibodies and subsequently challenged intravenously with the pathogenic SHIV(SF162P4) isolate. As compared to non-vaccinated animals (one of which died from AIDS 16 weeks post-exposure) the vaccinated macaques had lower levels of peak viremia, rapidly cleared virus from the periphery and developed delayed seroconversion to SIV core antigens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11595289     DOI: 10.1016/s0165-2478(01)00265-6

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  10 in total

1.  Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.

Authors:  Indresh K Srivastava; Keating VanDorsten; Lucia Vojtech; Susan W Barnett; Leonidas Stamatatos
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

2.  Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant.

Authors:  Susan W Barnett; Brian Burke; Yide Sun; Elaine Kan; Harold Legg; Ying Lian; Kristen Bost; Fengmin Zhou; Amanda Goodsell; Jan Zur Megede; John Polo; John Donnelly; Jeffrey Ulmer; Gillis R Otten; Christopher J Miller; Michael Vajdy; Indresh K Srivastava
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

3.  Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.

Authors:  Gerald V Quinnan; Xiao-Fang Yu; Mark G Lewis; Peng Fei Zhang; Gerd Sutter; Peter Silvera; Ming Dong; Anil Choudhary; Phuong T N Sarkis; Peter Bouma; Zhiqiang Zhang; David C Montefiori; Thomas C Vancott; Christopher C Broder
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.

Authors:  Megan C Wise; Natalie A Hutnick; Justin Pollara; Devin J F Myles; Constance Williams; Jian Yan; Celia C LaBranche; Amir S Khan; Niranjan Y Sardesai; David Montefiori; Susan W Barnett; Susan Zolla-Pazner; Guido Ferrari; David B Weiner
Journal:  J Virol       Date:  2015-06-17       Impact factor: 5.103

5.  Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.

Authors:  Ying Lian; Indresh Srivastava; V Rául Gómez-Román; Jan Zur Megede; Yide Sun; Elaine Kan; Susan Hilt; Susan Engelbrecht; Sunee Himathongkham; Paul A Luciw; Gillis Otten; Jeffrey B Ulmer; John J Donnelly; Dietmar Rabussay; David Montefiori; Estrelita Janse van Rensburg; Susan W Barnett
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

6.  Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Elaine Kan; Michael Vajdy; Ying Lian; Susan Hilt; Loic Martin; Claudio Vita; Ping Zhu; Kenneth H Roux; Lucia Vojtech; David C Montefiori; John Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques.

Authors:  Patricia Polacino; Kay Larsen; Lindsey Galmin; John Suschak; Zane Kraft; Leonidas Stamatatos; David Anderson; Susan W Barnett; Ranajit Pal; Kristen Bost; A H Bandivdekar; Christopher J Miller; Shiu-Lok Hu
Journal:  J Med Primatol       Date:  2008-12       Impact factor: 0.667

8.  Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines.

Authors:  Jan zur Megede; Gillis R Otten; Barbara Doe; Hong Liu; Louisa Leung; Jeffrey B Ulmer; John J Donnelly; Susan W Barnett
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.

Authors:  Petra Mooij; Ivonne G Nieuwenhuis; Christiaan J Knoop; Robert W Doms; Willy M J M Bogers; Peter J F Ten Haaft; Henk Niphuis; Wim Koornstra; Kurt Bieler; Josef Köstler; Brør Morein; Aurelio Cafaro; Barbara Ensoli; Ralf Wagner; Jonathan L Heeney
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.

Authors:  David Davis; Wim Koornstra; Zahra Fagrouch; Ernst J Verschoor; Jonathan L Heeney; Willy M J M Bogers
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.